Birmingham Biotech
Powered by Biomat — Advancing a World-Class Biomaterial Healthcare Platform
About Us
Birmingham Biotech LTD and Birmingham Biomat LTD are building a world-class biomaterial and mucosal protection platform through close collaboration with the University of Birmingham. Led by internationally recognised scientists such as Professor Liam Grover (FMedSci) and Dr. Richard Moakes, we unite academic excellence with commercial execution to deliver scientifically led, drug-free healthcare innovations designed for global impact.
Our Focus
- Birmingham Biomat – the dedicated R&D and platform innovation hub, advancing novel biomaterial-based healthcare technologies with preventive and therapeutic potential.
- Birmingham Biotech – responsible for regulatory approval, GMP manufacturing, and worldwide market deployment, ensuring innovations achieve safe and scalable access worldwide.
Our Portfolio
- NoriZite® – internationally recognised nasal sprays providing everyday, drug-free respiratory protection through barrier technology.
- Rinofast® – paediatric nasal care solutions designed for gentle, effective daily protection in children and infants.
- NoriZite® Eye Spray – a barrier spray offering long-lasting hydration and comfort for individuals experiencing dry eye or ocular irritation.
- RiNOZiTE® – intimate health gel certified under European medical device standards, delivering safe hydration, comfort, and protective care.
- Pipeline innovations – including wound-healing membranes, anti-fibrosis sprays, and other biomaterial-based preventive healthcare solutions.
Our Vision
By collaborating with world-leading academics and institutions, we are setting a global benchmark for drug-free prevention and care. Our platform-driven approach strengthens healthcare resilience, supports healthy ageing, and delivers sustainable innovations that improve quality of life for millions worldwide.
Our Team
Birmingham Biotech and Birmingham Biomat are led by a founding team that combines world-class biomaterials science, product and process engineering, and global commercial execution – bringing drug-free, biomaterial-based innovations all the way from laboratory concept to international markets.
Technology and life-sciences entrepreneur with over 15 years’ experience building and scaling innovation-driven companies, specialising in taking IP from lab to launch, cross-border business development and introducing new biomaterial-based products into global healthcare systems.
Michael Hsu
Founder & CEO
Professor of Biomaterials Science and Head of the School of Chemical Engineering at the University of Birmingham, and the founding Director of the Healthcare Technologies Institute. He is a world-leading biomaterials innovator and co-inventor of the elastic-templated bio-barrier technology, with over 30 patent filings, five products taken from concept to first-in-human trials (including two now available internationally) and more than £50 million in competitively awarded research funding, including a UK government-backed Innovation Accelerator in Medical Technology.
Prof. Liam Grover (FMedSci)
Co-founder and Chief Scientist
Associate Professor in Healthcare Materials and a co-inventor of the nasal spray technology, specialising in soft-materials formulation and mucosal delivery; he has taken multiple new therapies into clinical trials and one technology all the way to market.
Dr. Richard Moakes
Co-founder and Head of Formulation
A pharmaceutical scientist by training, with a PhD in photobiology in cancer therapeutics and more than a decade of research experience in drug delivery and translational nanomedicine at leading UK universities, she leads BHM’s technology and process development, working with universities, research institutes and manufacturing partners to translate biomaterial innovations into robust, scalable and manufacturable products that meet real-world clinical and consumer needs.
Dr. Julie Tzu-Wen Wang
Chief Technology Officer
Always feel no time for cold?
Choose NoriZite to get back to what matters